Aspire Biopharma Holdings (ASBP) Common Equity (2021 - 2026)

Aspire Biopharma Holdings (ASBP) has reported Common Equity for 6 consecutive years, with $11.8 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Common Equity rose 222.26% year-over-year to $11.8 million in Q2 2026; TTM through Jun 2026 was $11.8 million, a 222.26% increase from a year earlier, with the FY2025 full-year figure at -$6.4 million, down 314.02% from the prior year.
• Common Equity was $11.8 million for Q2 2026 at Aspire Biopharma Holdings, up from $3.9 million in the prior quarter.
• Over five years, Common Equity peaked at $11.8 million in Q2 2026 and troughed at -$11.5 million in Q3 2025.
• A 5-year average of -$4.0 million and a median of -$4.0 million in 2024 frame the typical range for Common Equity.
• Across the five-year window, Common Equity sank 3437196.79% in 2022 and soared 222.26% in 2026, its largest moves.
• Over 5 years, Common Equity stood at -$9.9 million in 2022, then jumped by 95.09% to -$487861.0 in 2023, then tumbled by 215.68% to -$1.5 million in 2024, then tumbled by 314.02% to -$6.4 million in 2025, then surged by 284.4% to $11.8 million in 2026.
• The last three Common Equity figures came in at $11.8 million (Q2 2026), $3.9 million (Q1 2026), and -$6.4 million (Q4 2025), per Business Quant data.